

Jean Charles Nault

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4729887/publications.pdf>

Version: 2024-02-01

99
papers

10,395
citations

61945

43
h-index

36008

97
g-index

103
all docs

103
docs citations

103
times ranked

12314
citing authors

#	ARTICLE	IF	CITATIONS
1	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. <i>Nature Genetics</i> , 2015, 47, 505-511.	9.4	1,372
2	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 149, 1226-1239.e4.	0.6	980
3	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. <i>Journal of Hepatology</i> , 2017, 67, 727-738.	1.8	525
4	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. <i>Nature Communications</i> , 2013, 4, 2218.	5.8	513
5	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. <i>Nature Genetics</i> , 2015, 47, 1187-1193.	9.4	387
6	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. <i>Journal of Hepatology</i> , 2012, 56, 184-191.	1.8	354
7	Advances in molecular classification and precision oncology in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 215-229.	1.8	311
8	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. <i>Gastroenterology</i> , 2013, 145, 176-187.	0.6	302
9	Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. <i>Gastroenterology</i> , 2017, 152, 880-894.e6.	0.6	290
10	Percutaneous treatment of hepatocellular carcinoma: State of the art and innovations. <i>Journal of Hepatology</i> , 2018, 68, 783-797.	1.8	271
11	Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. <i>Hepatology</i> , 2014, 60, 1983-1992.	3.6	268
12	Hepatocellular Benign Tumors From Molecular Classification to Personalized Clinical Care. <i>Gastroenterology</i> , 2013, 144, 888-902.	0.6	251
13	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. <i>Cancer Cell</i> , 2014, 25, 428-441.	7.7	240
14	Genotype-phenotype correlation of CTNNB1 mutations reveals different Wnt/catenin activity associated with liver tumor progression. <i>Hepatology</i> , 2016, 64, 2047-2061.	3.6	222
15	Genetic profiling of hepatocellular carcinoma using next-generation sequencing. <i>Journal of Hepatology</i> , 2016, 65, 1031-1042.	1.8	219
16	Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. <i>Journal of Experimental Medicine</i> , 2011, 208, 1359-1366.	4.2	218
17	Macrotrabecular massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. <i>Hepatology</i> , 2018, 68, 103-112.	3.6	159
18	The role of telomeres and telomerase in cirrhosis and liver cancer. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2019, 16, 544-558.	8.2	154

#	ARTICLE	IF	CITATIONS
19	Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. <i>Gastroenterology</i> , 2019, 156, 492-509.	0.6	145
20	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. <i>Gastroenterology</i> , 2019, 157, 760-776.	0.6	141
21	Genetics of Hepatobiliary Carcinogenesis. <i>Seminars in Liver Disease</i> , 2011, 31, 173-187.	1.8	138
22	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. <i>Hepatology</i> , 2020, 71, 164-182.	3.6	129
23	Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. <i>Gut</i> , 2015, 64, 820-829.	6.1	127
24	Safety and Efficacy of Irreversible Electroporation for the Treatment of Hepatocellular Carcinoma Not Amenable to Thermal Ablation Techniques: A Retrospective Single-Center Case Series. <i>Radiology</i> , 2017, 284, 877-886.	3.6	120
25	Molecular classification of hepatocellular adenoma in clinical practice. <i>Journal of Hepatology</i> , 2017, 67, 1074-1083.	1.8	119
26	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. <i>Nature Communications</i> , 2018, 9, 5235.	5.8	118
27	Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. <i>Gut</i> , 2022, 71, 616-626.	6.1	106
28	Biomarkers for Hepatobiliary Cancers. <i>Hepatology</i> , 2021, 73, 115-127.	3.6	104
29	Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. <i>Journal of Hepatology</i> , 2016, 65, 663-665.	1.8	103
30	The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 990-1002.	1.8	101
31	Hepatocellular Carcinoma within Milan Criteria: No-Touch Multibipolar Radiofrequency Ablation for Treatment—Long-term Results. <i>Radiology</i> , 2016, 280, 611-621.	3.6	100
32	The role of molecular enrichment on future therapies in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 237-247.	1.8	95
33	TERT promoter mutations in primary liver tumors. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 9-14.	0.7	78
34	Adeno-associated virus in the liver: natural history and consequences in tumour development. <i>Gut</i> , 2020, 69, 737-747.	6.1	78
35	A 17 β -Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. <i>Hepatology</i> , 2019, 70, 231-240.	3.6	75
36	Intratumor Molecular and Phenotypic Diversity in Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 1786-1788.	3.2	73

#	ARTICLE	IF	CITATIONS
37	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. <i>International Journal of Cancer</i> , 2019, 144, 533-544.	2.3	72
38	Serum Proteoglycans as Prognostic Biomarkers of Hepatocellular Carcinoma in Patients with Alcoholic Cirrhosis. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1343-1352.	1.1	65
39	Pathogenesis of hepatocellular carcinoma according to aetiology. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 937-947.	1.0	59
40	Genetics of hepatocellular carcinoma: The next generation. <i>Journal of Hepatology</i> , 2014, 60, 224-226.	1.8	59
41	Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity <i>In Vitro</i> . <i>Clinical Cancer Research</i> , 2017, 23, 4364-4375.	3.2	57
42	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. <i>Journal of Hepatology</i> , 2021, 74, 1155-1166.	1.8	54
43	Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making. <i>Seminars in Liver Disease</i> , 2014, 34, 363-375.	1.8	47
44	Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2018, 69, 336-344.	1.8	47
45	Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors. <i>Digestive and Liver Disease</i> , 2015, 47, 869-876.	0.4	46
46	Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. <i>Modern Pathology</i> , 2016, 29, 43-50.	2.9	45
47	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. <i>Journal of Hepatology</i> , 2020, 72, 924-936.	1.8	44
48	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. <i>Hepatology</i> , 2018, 68, 964-976.	3.6	43
49	Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. <i>Oncolmmunology</i> , 2013, 2, e27090.	2.1	39
50	Milestones in the pathogenesis and management of primary liver cancer. <i>Journal of Hepatology</i> , 2020, 72, 209-214.	1.8	39
51	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. <i>Lancet Oncology</i> , The, 2022, 23, 161-171.	5.1	36
52	Molecular classification of hepatocellular adenomas: impact on clinical practice. <i>Hepatic Oncology</i> , 2018, 5, HEP04.	4.2	34
53	Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma. <i>Oncolmmunology</i> , 2019, 8, 1615818.	2.1	34
54	Natural history of liver adenomatosis: A long-term observational study. <i>Journal of Hepatology</i> , 2019, 71, 1184-1192.	1.8	32

#	ARTICLE	IF	CITATIONS
55	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. <i>Journal of Hepatology</i> , 2017, 66, 734-742.	1.8	31
56	Molecular Classification of Hepatocellular Adenomas. <i>International Journal of Hepatology</i> , 2013, 2013, 1-7.	0.4	24
57	Multibipolar Radiofrequency Ablation for the Treatment of Mass-Forming and Infiltrative Hepatocellular Carcinomas > 5 cm: Long-Term Results. <i>Liver Cancer</i> , 2019, 8, 172-185.	4.2	22
58	TIPS for management of portal-hypertension-related complications in patients with cirrhosis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 249-263.	0.7	22
59	Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma. <i>Immunotherapy</i> , 2019, 11, 1005-1013.	1.0	21
60	Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. <i>Liver International</i> , 2022, 42, 492-506.	1.9	20
61	Optimizing curative management of hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 109-115.	1.9	19
62	Recurrent chromosomal rearrangements of <i>ROS1</i> , <i>FRK</i> and <i>IL6</i> activating JAK/STAT pathway in inflammatory hepatocellular adenomas. <i>Gut</i> , 2020, 69, 1667-1676.	6.1	17
63	Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma. <i>New England Journal of Medicine</i> , 2018, 379, 1178-1180.	13.9	15
64	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	1.9	15
65	Transarterial chemoembolization for early stage hepatocellular carcinoma decrease local tumor control and overall survival compared to radiofrequency ablation. <i>Oncotarget</i> , 2017, 8, 32190-32200.	0.8	15
66	The CRP level and STATE score predict survival in cirrhotic patients with hepatocellular carcinoma treated by transarterial embolization. <i>Digestive and Liver Disease</i> , 2016, 48, 1088-1092.	0.4	14
67	Virologic control and severity of liver disease determine survival after radiofrequency ablation of hepatocellular carcinoma on cirrhosis. <i>Digestive and Liver Disease</i> , 2019, 51, 86-94.	0.4	14
68	Adeno-associated virus type 2 as an oncogenic virus in human hepatocellular carcinoma. <i>Molecular and Cellular Oncology</i> , 2016, 3, e1095271.	0.3	12
69	Characterizing the mechanism behind the progression of NAFLD to hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2020, 7, HEP36.	4.2	12
70	Type 2 diabetes-associated hepatocellular carcinoma: A molecular profile. <i>Clinical Liver Disease</i> , 2016, 8, 53-58.	1.0	11
71	Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study. <i>Liver International</i> , 2022, 42, 1891-1901.	1.9	11
72	Benign liver tumours: understanding molecular physiology to adapt clinical management. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 703-716.	8.2	11

#	ARTICLE	IF	CITATIONS
73	Primary Liver Carcinomas Can Originate From Different Cell Types: A New Level of Complexity in Hepatocarcinogenesis. <i>Gastroenterology</i> , 2013, 145, 53-55.	0.6	10
74	Percutaneous Treatment of Localized Infiltrative Hepatocellular Carcinoma Developing on Cirrhosis. <i>Annals of Surgical Oncology</i> , 2016, 23, 1906-1915.	0.7	8
75	Autoimmune-like chronic hepatitis induced by olmesartan. <i>Hepatology</i> , 2017, 66, 2086-2088.	3.6	8
76	A Dive Into the Deep Heterogeneity of Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2019, 157, 1477-1479.	0.6	8
77	Percutaneous radiofrequency ablation for hepatocellular carcinoma developed on non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 905-917.	1.9	8
78	Reports from the International Liver Cancer Association (ILCA) congress 2014. <i>Journal of Hepatology</i> , 2015, 62, 477-482.	1.8	7
79	Molecular targets for HCC and future treatments. <i>Journal of Hepatology</i> , 2017, 66, 234-235.	1.8	7
80	Genomics of Viral Hepatitis-Associated Liver Tumors. <i>Journal of Clinical Medicine</i> , 2021, 10, 1827.	1.0	7
81	Performance of non-invasive biomarkers compared with invasive methods for risk prediction of posthepatectomy liver failure in hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2022, 109, 455-463.	0.1	7
82	Stemness of liver cancer: From hepatitis B virus to Wnt activation. <i>Journal of Hepatology</i> , 2016, 65, 873-875.	1.8	6
83	The transcriptomic G1-G6 signature of hepatocellular carcinoma in an Asian population. <i>Medicine (United States)</i> , 2016, 95, e5263.	0.4	6
84	Transient elastography predicts survival after radiofrequency ablation of hepatocellular carcinoma developing on cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 142-150.	1.4	5
85	Can We Move on From the Discussion of Direct Antiviral Agents and Risk of Hepatocellular Carcinoma Recurrence?. <i>Gastroenterology</i> , 2019, 156, 1558-1560.	0.6	4
86	Molecular Determinants of Prognosis in Hepatocellular Carcinoma. <i>Journal of Clinical and Translational Hepatology</i> , 2014, 2, 31-6.	0.7	3
87	Cancer Gene Discovery in Hepatocellular Carcinoma: The CRISPR/CAS9 Accelerator. <i>Gastroenterology</i> , 2017, 152, 941-943.	0.6	3
88	<i>RSPO2</i> abnormal transcripts result from read-through in liver tumours with high β -catenin activation and <i>CTNNB1</i> mutations. <i>Gut</i> , 2020, 69, 1152-1153.	6.1	3
89	Acute pericarditis: A rare complication of gastric variceal obturation with cyanoacrylate glue. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, e25-e28.	0.7	3
90	NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF BENIGN LIVER TUMOURS. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 46, 101765.	0.7	3

#	ARTICLE	IF	CITATIONS
91	Next generation sequencing, inter-tumor heterogeneity and prognosis of hepatitis B related hepatocellular carcinoma. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2014, 26, 730-1.	0.7	3
92	Portal hypertension and hepatocellular carcinoma: Navigating uncharted waters. United European Gastroenterology Journal, 2022, 10, 8-9.	1.6	3
93	Hepatocellular Carcinoma: the Impact of NAFLD. Current Hepatology Reports, 2016, 15, 190-198.	0.4	2
94	Reply to: "Response to: Positron emission tomography/computed tomography with 18 F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma" Journal of Hepatology, 2018, 69, 555-556.	1.8	2
95	Percutaneous ablation for locally advanced hepatocellular carcinoma with tumor portal invasion. Clinics and Research in Hepatology and Gastroenterology, 2021, 45, 101731.	0.7	2
96	Predisposition to hepatocellular carcinoma: Clues in sex chromosomes. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 547-548.	0.7	0
97	Percutaneous treatments of hepatocellular carcinoma: Improving efficacy, applicability and extending ablation criteria. Liver Cancer International, 0, , .	0.2	0
98	Structure, Dynamics, and Impact of Replication Stress-Induced Structural Variants in Hepatocellular Carcinoma. Cancer Research, 2022, 82, 1470-1481.	0.4	0
99	Impact of Extended Use of Ablation Techniques in Cirrhotic Patients with Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. Cancers, 2022, 14, 2634.	1.7	0